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INTRODUCTION 
In June 1999, the Association of British Neurologists (ABN) first published guidelines for the 
use of the licensed multiple sclerosis (MS) disease-modifying treatments (at that time ß-
interferon and glatiramer acetate). The guidelines were revised in 2001 and have been 
periodically updated since then. In 2002, following the negative assessment of these 
treatments by the National Institute of Clinical Excellence (NICE), the MS risk-sharing 
scheme started, in which patients eligible according to the 2001 ABN guidelines were 
provided with treatment funded through the UK National Health Service (NHS), and 
monitored annually for up to 10 years (1). Recruitment to the risk-sharing scheme cohort is 
complete. Pending a future final evaluation, the UK Department of Health’s instruction to 
NHS funders remains in place: that patients who fulfil the ABN criteria should continue to 
receive treatment funded through the NHS. The British neurological community has fully 
accepted the risk-sharing scheme for prescribing ß-interferon and glatiramer acetate. 
Approximately 70 ‘treating centres’ have recruited over 5000 patients between 2002 and 
2005, and these have been monitored annually for 10 years; many more patients have 
received these treatments since 2005. The ABN published revised guidelines in 2007, and 
then again in 2009, following the licensing of natalizumab and mitoxantrone.  
 
This 2015 revised guideline replaces former versions. It includes all newly approved or 
licensed treatments for multiple sclerosis and represents a consensus concerning their use. 
These guidelines will require future revision as other treatments receive approval (e.g., 
daclizumab and ocrelizumab): we suggest they are reviewed after an interval of no longer 
than 12 months. The guideline is not intended to provide a complete description of the 
possible complications and monitoring of disease-modifying treatments in multiple sclerosis; 
we refer prescribing neurologists to the relevant summaries of product characteristics. 
 
 
BACKGROUND 
Multiple sclerosis is a complex disease. Perhaps uniquely in neurology, its clinical course is 
characterised by two quite different clinical phases: the relapsing–remitting phase and a 
phase of progressive disease. The relationship between relapse and progression is not well 
understood. The clinical picture is made the more complicated by the fact that a minority of 
patients experience only one or the other of these ‘phases’; while in the remaining majority of 
patients the phases overlap, though over varying lengths of time. Given [1] this unpredictable 
period of overlap and [2] that relapses differ significantly in their duration and [3] that in 
progressive disease the rate of deterioration can vary substantially (even longitudinally in the 
same individual), it can be difficult to mark the transition from relapsing–remitting disease to 
progressive multiple sclerosis, so this is commonly done only in retrospect.   
 
In the individual patient, multiple sclerosis remains a fundamentally unpredictable condition. 
There are many factors that influence prognosis and disease course, including sex, relapse 
frequency, type of relapse, age, MRI lesion load and spinal cord involvement. However, for 
most patients, multiple sclerosis results in a gradual accumulation of fixed neurological 
disability over time. There is an increasing tendency to use treatment earlier and more 
aggressively in those people deemed to have a worse outlook, but there is limited direct 
evidence of long-term benefit for making such decisions. The ABN strongly supports the 
collection of long term and collaborative research and data to facilitate better patient–doctor 
decisions.  
 
Disease-modifying treatments clearly impact significantly on multiple sclerosis, and the ABN 
recommends starting treatment as early as possible in eligible patients. The complexities 
and uncertainties that we have outlined, combined with the now significant range of 
treatments available for relapsing–remitting multiple sclerosis, make treatment decisions 
complex for both patient and neurologist. We stress the importance of shared conversations 
about disease activity, risk and benefit, to make the choice that is right for the individual and 
their circumstances. Furthermore, the ABN believes that people with multiple sclerosis 
should be managed by neurologists* with specialist experience of managing patients with 
this condition and who have the capacity to manage safety monitoring. It is essential that 
multiple sclerosis specialist neurologists can prescribe the full range of available licensed 
treatments according to what is clinically appropriate and best meets individual needs. 
 
After considering the evidence, the following summary statements can be made concerning 
the use of disease-modifying drugs in treating multiple sclerosis:- 
1. All of the licensed disease-modifying treatments for multiple sclerosis—ß-interferons, 
glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, natalizumab, and 
alemtuzumab—reduce relapse rate and MRI lesion accumulation in relapsing–
remitting MS, to varying extents (2). There are relatively few comparison trials (3-7), 
and so information on comparative efficacy is usually inferential. Care must be taken 
with a direct ‘inter-trial’ comparison of the compounds, since the pivotal trials will 
have occurred at differing time points and there are confounders (known and 
unknown)—control groups, for example, may differ remarkably between different 
trials. Nonetheless, we suggest that these seven agents can be divided into two 
broad classes: drugs of moderate efficacy (average relapse reduction in 30–50% 
range), including the ß-interferons, glatiramer, teriflunomide, dimethyl fumarate and 
fingolimod; and drugs of high efficacy (average relapse reduction substantially more 
than 50%), alemtuzumab and natalizumab. Side effect profiles vary considerably 
between the drugs. 
2. Mitoxantrone has significant adverse effects and is not obviously superior in efficacy 
to the newer drugs of high efficacy. It is not licensed for multiple sclerosis in the UK, 
but is still used, if infrequently, on an off-label basis.   
3. Although it seems plausible that reducing relapse rate and MRI lesion accumulation 
would favourably influence the long term prognosis, natural history data show only a 
weak correlation between long-term disability and relapse frequency (8, 9). Some 
trials have reported reduced accumulation of disability over 2–3 years, even with 
relatively modestly effective drugs such as ß-interferon (10, 11); others have not (12-
14). Similarly, some uncontrolled long-term data (up to 16 years) suggest the 
disease-modifying therapies reduce the accumulation of disability (15); other studies 
suggest not (16, 17). There are no published and peer-reviewed controlled trial 
results showing long-term benefit (although it is very challenging to perform 
controlled trials over periods longer than 2–3 years).  
4. There is a consensus that none of the currently available disease-modifying 
therapies significantly modifies progressively increasing disability that is unrelated to 
relapses (progressive non-relapsing multiple sclerosis) (18-20). It is also not 
established securely that giving long-term disease-modifying therapy (a) reduces the 
accumulation of disability by whatever mechanism or (b) prevents or slows entry to 
the secondary progressive stage of the disease. The ABN calls for more research 
addressing these important issues. The implication, however, is that no disease-
modifying treatment is effective, or indicated, in patients with established progressive 
multiple sclerosis in the absence of relapses. 
                                               
*
We are not aware of any generally accepted definition of ‘multiple sclerosis specialist neurologist’. Our view 
is that an effective and safe multiple sclerosis team, whether based at a Regional Neuroscience Centre or a 
District General Hospital, should include more than one multiple sclerosis specialist consultant neurologist 
working with an appropriately experienced multidisciplinary health care team. It is very difficult for a single 
consultant neurologist interested in multiple sclerosis working in isolation to maintain his or her specialist 
skills in multiple sclerosis. 
5. It is not yet clear whether treatment should aim for a target such as ‘no evidence of 
disease activity’—either clinical or radiological. At present there is no evidence upon 
which to offer guidance—whether patients on treatment experiencing, say, one 
relapse every five years fare worse over a 10-year time frame than those who have 
no relapses is not known. Therefore, whether a single relapse should trigger an 
immediate treatment escalation is not known. Again, more research is needed. 
6. New MRI lesions are a more sensitive index of inflammatory disease activity than 
clinical relapses, occurring up to ten times more frequently than clinically eloquent 
relapses (21). Accordingly, many now substitute MRI activity for clinical activity in the 
classification, diagnosis and management of multiple sclerosis. For instance, people 
previously considered to have a ‘clinically isolated syndrome’ may now be diagnosed 
as having multiple sclerosis, under the 2010 McDonald criteria, if there is evidence of 
spatial and temporal dispersion of MRI lesions (22). Recently, the European 
Medicines Agency has explicitly recognised that multiple sclerosis may be defined as 
‘active’ on radiological or clinical evidence.  
7. There has been significant progress in assessing MRI activity over 12-month 
intervals, combined with clinical relapse activity, to prognosticate—for example, the 
modified Rio criteria in patients receiving ß-interferon (23)—so that, ultimately, 
treatment decisions might be tailored accordingly; the ABN encourages further such 
research. Meanwhile, particularly in the first years after diagnosis, it is appropriate to 
consider including MRI scanning during the annual review recommended by 2014 
NICE Clinical Guideline for the management of multiple sclerosis [NICE CG186], 
both on grounds of monitoring efficacy and (with many agents) safety. By implication, 
this annual review will need to be conducted by the multiple sclerosis specialist 
neurologist who is also best placed to determine if MRI scanning is required. 
8. There are now many people with relatively long-standing relapsing–remitting multiple 
sclerosis who have used ß-interferons or glatiramer for perhaps several years and 
whose disease is stable clinically. It is unclear whether such patients would benefit 
from MRI monitoring.  
9. Immunotherapies appear particularly helpful when given early to people with active 
relapsing–remitting disease, before there is fixed disability or secondary progression. 
For instance, there was dramatic benefit in a clinical trial of a cohort with fewer than 
two years’ disease duration, a mean EDSS of 2.0, and more than two relapses/year 
(24). 
10. MS specialist neurologists may adopt either an ‘escalation’ strategy or an ‘induction’ 
strategy in treating multiple sclerosis. The ‘escalation’ strategy involves starting with 
the drug that is considered the least toxic but which will control the patient’s disease, 
and escalating to more potent therapies in the face of continued disease activity. An 
‘induction’ strategy involves giving a powerful drug, with significant side effects, early 
in the disease; an example of this is the alemtuzumab trials. We clearly require long-
term data comparing the benefits and risks of these approaches. 
11. As newer treatments emerge and when there is clinical equipoise agreed between 
clinician and patient, and there are clinical trials available for recruitment, 
then patients should be offered participation in relevant studies. 
12. UK health systems have diverged with the devolved administrations, not least in 
respect of treatment guidelines and/or restrictions. These differences render it now 
impossible to make treatment recommendations that are simultaneously compliant 
with all of the relevant advisory or statutory medicines agencies (NICE, SMC, etc.). 
Therefore this current document takes a pragmatic approach based on best clinical 
practice and the licensed indications of each therapeutic agent. The ABN continues 
to support a fundamental principle of the NHS that, despite these changes, all 
patients have a right to access the appropriate expertise and therapy. 
 
 
GENERAL MANAGEMENT ADVICE 
Disease-modifying treatment should be started and supervised by a multiple sclerosis 
specialist neurologist. When considering potential disease-modifying treatment options, it is 
important that patients and neurologists fully appreciate the risk and benefit of drugs, and of 
leaving the disease untreated. It is important from the outset to give patients accurate 
information on the expectations of treatment, including the evidence that disease-modifying 
treatment efficacy can be only partial, moderate and not curative. Patients should also 
discuss the risk as well as expected benefit of treatment; monitoring requirements; and work, 
family and other factors that are personally important, and clinicians should take account of 
their views in making the treatment selection. 
 
Multiple sclerosis specialist nurses play a vital role in ensuring that the treatment pathways 
are followed, managing symptoms, and providing education, information and reassurance to 
patients during and between clinic attendances. In many centres, multiple sclerosis specialist 
nurses play a key role in supporting patients through the process of making choices about 
treatment options as well as monitoring patients on these often complex treatments. 
 
Patients can also obtain information from patient groups, particularly the Multiple Sclerosis 
Trust and the Multiple Sclerosis Society, which have produced information leaflets in plain 
language, as well as a range of leaflets on other symptomatic, psychological and social 
aspects of living with multiple sclerosis. There are also several excellent websites 
particularly targeted towards patients, providing valuable information and guidance. 
 
Once started on therapy, patients should remain under the supervision of specialist multiple 
sclerosis neurologists and nurses; an important aim of this is to encourage adherence to a 
monitoring protocol tailored to the safety profile, and recommended risk monitoring 
programme of the individualised therapy. Continued supervision by the specialist multiple 
sclerosis team is essential to assess treatment effectiveness and to document relapses. 
Different disease-modifying treatments require varied pre-treatment investigations and 
ongoing monitoring, some of which may be devolved to the general practitioner. However, it 
is important that the multiple sclerosis neurology centre continues to supervise the care of 
patients on disease-modifying treatments, to identify side effects and assess therapeutic 
efficacy.   
 
In Europe and the USA it is common practice to use MRI to monitor disease activity in 
patients on disease-modifying treatments. This is increasingly part of regular practice in the 
UK, and may help in decisions concerning either the escalation or the stopping of 
treatments. There is limited direct evidence upon which to base the frequency of imaging 
and we require more research on this topic. Serial MR imaging is particularly important 
during treatment with natalizumab. Neuroscience centres with expertise in multiple sclerosis 
will increasingly need ready access to MRI and other investigatory services, such as cardiac 
monitoring or optical coherence tomography, in order to monitor disease-modifying 
treatments safely.    
  
 
RECOMMENDATIONS FOR STARTING DISEASE-MODIFYING TREATMENT 
Eligible patients will normally be ambulant (maximum EDSS 6.5). There are no treatments 
licensed for use during pregnancy (but see below).  
 
As mentioned above, the currently licensed disease-modifying treatments divide broadly into 
two classes: -  
 drugs of moderate efficacy [‘Category 1’] 
 ß-interferons (including ‘pegylated’ ß-interferon) 
 glatiramer acetate 
 teriflunomide 
 dimethyl fumarate 
 fingolimod 
  drugs of high efficacy [‘Category 2’] 
 alemtuzumab 
 natalizumab 
 
 
A. Relapsing–Remitting multiple sclerosis 
Patients with relapsing–remitting multiple sclerosis who have had two or more clinical 
relapses in the previous two years are considered to have ‘active’ disease that warrants 
consideration of disease-modifying treatments. Increasingly, clinicians are starting 
treatments in people whose disease is judged ‘active’ because of a single recent relapse 
and/or on radiological grounds, including both patients newly diagnosed according to the 
2010 ‘MacDonald criteria’ (21), and those with longer established disease who develop new 
MRI lesions without clinical relapse. As mentioned above, the European Medicines Agency 
has explicitly recognised that disease activity may be established on radiological or clinical 
grounds (in its licensing of alemtuzumab).  
 
All individuals with active relapsing–remitting multiple sclerosis should be considered 
expeditiously for treatment. Most are likely to start treatment with a Category 1 drug. It 
seems likely that dimethyl fumarate and fingolimod are the more effective drugs in this 
category, with the advantage of being oral agents. Some people with active disease will 
prefer, together with their neurologist, to start dimethyl fumarate or, if ‘highly active,’ 
fingolimod in this group. (In some, one of the Category 2 drugs may be appropriate; see 
below.) ß-interferon, teriflunomide and glatiramer acetate, which appear broadly to be 
equally effective, are probably a little less effective than dimethyl fumarate or fingolimod. 
However, the ß-interferons and glatiramer acetate have been used extensively for decades 
in multiple sclerosis, and there is a wealth of clinical experience confirming their general 
safety. Individuals with relatively quiescent disease, and/or who are more risk-averse, might 
therefore be more likely to choose one of the ß-interferons or glatiramer acetate. Individuals 
with needle phobia may choose teriflunomide, dimethyl fumarate or, if eligible, fingolimod. 
There is increasing information on the long term safety profile of these newer agents and 
their use requires patients to be followed by multiple sclerosis specialist neurologists and 
nurses; those on ‘older’ agents also need specialist follow up to monitor and assess disease 
activity. 
 
B. More active relapsing–remitting multiple sclerosis 
Patients may be classified as having more active multiple sclerosis by frequent clinical 
relapses, and/or MRI activity, either when untreated or whilst on a category 1 drug. The 
formal criteria for high disease activity despite interferon-beta or glatiramer requires one 
relapse in the previous year on interferon-beta and either (a) ≥ 1 gadolinium-enhancing MRI 
lesions or (b) at least nine T2-hyperintensive lesions on cranial MRI.† We recommend that 
patients with more active disease use one of the Category 2 drugs, natalizumab or 
alemtuzumab. Indirect comparison suggests that alemtuzumab and natalizumab have similar 
                                               
†
In the licensing of natalizumab, “rapidly evolving severe multiple sclerosis” was defined as ≥ 2 disabling relapses 
in previous year (on or off therapy) and ≥ 1 gadolinium-enhancing MRI lesion or significant increase in MRI T2 
lesion load. 
efficacy. Although alemtuzumab’s licensed indication is much less restrictive, allowing for 
anyone to be treated with ‘active’ multiple sclerosis, defined clinically or radiologically (so 
allowing alemtuzumab to be used in contexts where natalizumab is not licensed) we 
recommend that, given its potential adverse effects, alemtuzumab should be mainly confined 
to patients with more active disease. Alemtuzumab and natalizumab are appropriate where 
individuals and their multiple sclerosis specialist neurologists are most concerned to achieve 
high efficacy, despite the more complex safety profile compared to Category 1 drugs. 
 
Some people who have experienced relapses despite using a Category 1 agent may be 
particularly risk averse. Others may have had infrequent or occasional minor relapses. In 
such instances, it may be appropriate to change from one to another Category 1 agent, 
rather than escalating to a Category 2 drug. In such instances, clinicians should bear in mind 
the likely greater potency of fingolimod and dimethyl fumarate compared to the interferons, 
glatiramer and teriflunomide. 
 
Switching between Category 1 agents because of continued disease activity may be justified 
on the basis of MRI-proven disease activity alone (i.e. without clinical relapses). By contrast, 
switching from a Category 1 agent to a Category 2 monoclonal antibody is probably 
justifiable only when there is clinical evidence of high disease activity despite treatment. We 
recognise, however, that rapid new MRI lesion acquisition, in the absence of clinical 
relapses, rarely may indicate sufficient disease activity to consider escalation to monoclonal 
antibodies rarely, despite there being no clear evidence base for this. We encourage more 
research into this question. 
 
 
C. Clinically isolated syndrome 
Various disease-modifying treatments can delay the diagnosis of multiple sclerosis in 
patients with a clinically isolated syndrome (25-29), though there is less secure evidence for 
their evidence long-term benefit (30, 31). Neurologists may consider advising treatment, 
after discussion with the patient concerning the risks and benefits, for individuals within 12 
months of a significant clinically isolated syndrome, if MRI evidence establishes a diagnosis 
of multiple sclerosis (2010 McDonald criteria [22]) or predicts a high likelihood of recurrent 
episodes (i.e. development of multiple sclerosis), and perhaps particularly if CSF 
examination shows CNS-restricted oligoclonal immunoglobulin bands. Currently, only the ß-
interferons and glatiramer are licensed for clinically isolated syndrome. 
 
D. People aged under 18 years 
We believe that minors aged between 16 and 18 years should be treated according to the 
above guidelines. Children with multiple sclerosis aged less than 16 should be treated in 
specialist clinics, preferably under a combined team including adult and paediatric 
neurologists with a particular interest in multiple sclerosis. 
 
 
E. Primary or secondary progressive multiple sclerosis 
None of the current disease-modifying treatments are recommended in non-relapsing 
secondary progressive multiple sclerosis, or in primary progressive multiple sclerosis. Some 
people with relapsing secondary progressive multiple sclerosis, whose relapses are their 
main cause of increasing disability, may benefit from disease-modifying treatment. 
 
 
 
 
 
 
 
 
Recommendations for stopping disease-modifying treatment 
Decisions to start or stop treatment, or to perform MRI for diagnosis and management, 
should recognise the central importance of patient choice; patients should be fully informed 
of relevant facts and uncertainties before making a decision with their multiple sclerosis 
specialist neurologist. It can be impossible in individual patients to be certain that a treatment 
is not helping. We believe it is not feasible to have mandatory stopping criteria that apply in 
all cases. The difficulty of stopping treatment in people with progressive disease is 
compounded by the absence of alternative options for disease modification—but this no 
argument for continuing an ineffective (and expensive) treatment. Clinicians should consider 
stopping disease-modifying treatment in the following scenarios: 
 
1.    Significant side effects specific to any individual agent should trigger withdrawal of 
that agent and consideration of an alternative treatment. 
 
2.    Development of non-relapsing secondary progressive multiple sclerosis. 
 
3.    Pregnancy. During pregnancy, disease-modifying treatments should normally be 
stopped, as stated in the summary of product characteristics. In anticipation of a planned 
pregnancy, patients should be advised that there is limited information on the risks of early 
fetal exposure to some disease-modifying treatments, while others have known 
teratogenicity. We therefore recommend that women stop disease-modifying treatments 
while trying to conceive unless, in the neurologist’s opinion the woman’s clinical condition 
requires treatment.  Given the increased risk of relapse in the puerperium, treatment should 
be restarted early after delivery, depending on discussions concerning breast-feeding. 
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